Disease-modifying drugs – molecular and clinical aspects

Disease-modifying antirheumatic drugs (DMARDs) are involved in the control of inflammation. A great number of mechanisms take part in the treatment procedures undertaken in rheumatoid arthritis and allied conditions. Inhibition of biological hyperreactivity is the most important phenomenon operating in the signal transduction cascade (cells, genes, molecules), following DMARDs therapy. Clinical remission can be achieved in approximately 50% of treated patients.

REFERENCES (16)

Smolen JS. Therapeutic Strategies for Rheumatoid Arthritis. Nat Rev 2003; 2: 473-488. .

Google Scholar

Mackiewicz S. Geneza reumatoidalnego zapalenia stawów. Reumatologia 2010; 48: 1-3. .

Google Scholar

Furst D, et al. Consensus Statement on Biological Agents. Ann Rheum Dis, Suppl 2007; 66 (suppl III): iii 2-22. .

Google Scholar

Trollmo C, Gudmundsson S, Feltelius N, et al. Sulphasalazine Inhibit Antigen Specific Immune Response in vivo. Ann Rheum Dis 2007; 66: 481-485. .

Google Scholar

Oerlemans R, et al. Sulphasalazine Sensitizes Human Monocytig Cells for Glucocorticoids. Ann Rheum Dis 2007; 66: 1289-1304. .

Google Scholar

Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low-dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006; 65: 285-293. .

Google Scholar

Mackiewicz S. Reumatoidalne zapalenie stawów – koncepcje patogenetyczne i terapeutyczne. Konferencja Reumatologiczna, Poznań 3-4.04.1997 r. .

Google Scholar

Croustein BM. Methotrexate, adenosine and blood flow. Ann Rheum Dis 2006; 65: 421-422. .

Google Scholar

Kremer J.M. Methotrexate Pharmacogenomics. Ann Rheum Dis 2006; 65: 1121-1123. .

Google Scholar

10.

Świerkot J, Ślęzak R, Karpiński P i wsp. Polimorfizm genu reduktazy metylenohydrofolianowej a skuteczność leczenia i działania niepożądane w terapii MTX chorych na reumatoidalne zapalenie stawów. Reumatologia 2010; 48: 81-93. .

Google Scholar

11.

Riksen NP, Barrera P, van den Broek PH, et al. Methotrexate Modulates the Kinetics of Adenosine in Human in vivo. Ann Rheum Dis 2006; 65: 465-470. .

Google Scholar

12.

Bijlsma JW, Weinblatt ME. Optimal use of methotrexate: the advantage of tight control. Ann Rheum Dis 2007; 66: 1409-1410. .

Google Scholar

13.

Verstappen SM, et al. Defensive Treatment with Methotrexate in Early Rheumatoid Arthritis. Ann Rheum Dis 2007; 66: 1443-1449. .

Google Scholar

14.

Rozin A, et al. Relapse of Rheumatoid Arthritis After Substitution of Oral for Parental MTX. Ann Rheum Dis 2010; 61: 756-757. .

Google Scholar

15.

Hafström I, Albertsson K, Boonen A, et al. Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. Ann Rheum Dis 2009; 68: 508-513. .

Google Scholar

16.

Mackiewicz S. Reumatoidalne zapalenie stawów – aspekt fenomenologiczny. Reumatologia 2007; 45: 55-58.

Google Scholar

Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Submit your paper

eISSN:	2084-9834
ISSN:	0034-6233